Protalix BioTherapeutics, Inc. has received $-0.11 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.13 while the top line estimate is $-0.09 , a key information to consider for Day Trading and investing in stocks.
Protalix BioTherapeutics, Inc. reported better than expected with a surprise EPS of 30% or $0.03 during its most recent quarterly earnings. The Actual EPS was $-0.07 compared to the Estimated EPS of $-0.1. Carmiel based Protalix BioTherapeutics, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 14, 2017.
In the last quarter, Protalix BioTherapeutics, Inc. reported Annual Earnings of $-0.07. Based on the filings, last years Annual Earnings was, $-0.29. In the last Quarter, PLX reported a surprise Earnings per Share of 30% . The consensus estimate for current quarter is $-0.11 and for the current fiscal year, the estimate is $-0.38. For the Next fiscal year, the estimate is $-0.32 based on the consensus.
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) : On Tuesday heightened volatility was witnessed in Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) which led to swings in the share price. The stock opened for trading at $0.62 and hit $0.6299 on the upside , eventually ending the session at $0.6299, with a gain of 2.89% or 0.0177 points. The heightened volatility saw the trading volume jump to 2,137,644 shares. The 52-week high of the share price is $0.96 and the company has a market cap of $78 million. The 52-week low of the share price is at $0.26 .
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalixs unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalixs first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.